A mouse monoclonal antibody against Epstein-Barr virus envelope glycoprotein 350 prevents infection both in vitro and in vivo.
A mouse monoclonal antibody (MAb) against Epstein-Barr virus (EBV) envelope glycoprotein 350, 72A1, inhibited EBV infection of B lymphocytes in vitro. When severe combined immunodeficient mice were injected with EBV-seronegative donors' peripheral-blood mononuclear cells and challenged with EBV, 72A1 MAb prevented development of EBV-positive tumors: none of the test mice (0/12) developed EBV-positive tumors. In contrast, 67% (8/12) of control mice developed EBV-positive tumors (P=.001). Purified 72A1 MAb was infused into 1 healthy adult and 4 EBV-seronegative children after liver transplant. No adverse reactions were seen in the adult or in 3 of the transplant recipients. The remaining patient developed a hypersensitivity reaction, thus underlining the need to humanize the MAb.
Haque
Tanzina
T
Molecular and Clinical Virology, University of Edinburgh, Summerhall, Edinburgh, United Kingdom. t.haque@medsch.ucl.ac.uk
Johannessen
Ingolfur
I
Dombagoda
Dilani
D
Sengupta
Chandrya
C
Burns
David M
DM
Bird
Pru
P
Hale
Geoff
G
Mieli-Vergani
Giorgina
G
Crawford
Dorothy H
DH
D000328:Adult; D000818:Animals; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D002051:Burkitt Lymphoma / Q000276:immunology / Q000517:prevention & control; D020031:Epstein-Barr Virus Infections / Q000276:immunology* / Q000517:prevention & control; D004854:Herpesvirus 4, Human / Q000276:immunology*; D006801:Humans; D051379:Mice; D016513:Mice, SCID; D014181:Transplantation Immunology
D000911:Antibodies, Monoclonal